Vyleesi (Bremelanotide) Adolescent (12-17) Transition to Adult Care

What Is Bremelanotide and Why Does Age Matter?

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist approved by the FDA in June 2019 under the brand name Vyleesi. Its labeled indication is hypoactive sexual desire disorder (HSDD) in premenopausal adult women. The drug works by activating MC3R and MC4R receptors in the central nervous system to modulate dopaminergic and noradrenergic pathways that underpin sexual desire. [1, 2]

Age matters for two reasons. First, the FDA approval is explicitly restricted to adults, meaning the safety and efficacy database contains no randomized controlled trial data from patients under 18. Second, adolescent neurodevelopment, hormonal flux during puberty, and incomplete myelination of prefrontal circuits all alter the pharmacodynamic environment in ways that have not been systematically studied for bremelanotide. [3]

FDA Labeling and the Under-18 Gap

The FDA prescribing information for bremelanotide (NDA 210557) states: "Safety and efficacy have not been established in pediatric patients." [1] That single sentence carries significant clinical weight. It means any use in a patient aged 12-17 is off-label, the prescriber assumes full medicolegal responsibility, and no insurance pathway exists for reimbursement in that age group under standard formularies.

Clinicians at pediatric sexual medicine programs occasionally encounter adolescents aged 16-17 presenting with distress related to absent or markedly reduced sexual desire. These cases typically involve comorbid depression treated with serotonin reuptake inhibitors (SSRIs), a drug class known to suppress desire. Paroxetine, for example, reduces sexual function scores in adolescents at rates similar to those seen in adults. [4] However, prescribing bremelanotide to address SSRI-induced HSDD in a 16-year-old is not supported by any guideline from the Endocrine Society, the American College of Obstetricians and Gynecologists (ACOG), or the FDA. [1, 5]

Neurodevelopmental Considerations in Adolescents

The hypothalamic-pituitary-gonadal (HPG) axis undergoes substantial reorganization between ages 12 and 18. Gonadotropin-releasing hormone (GnRH) pulse frequency, luteinizing hormone (LH) amplitude, and sex steroid concentrations all shift in a pattern that differs markedly from the adult state studied in bremelanotide trials. [6] Melanocortin signaling itself is intertwined with gonadotropin release. Research in animal models has shown that MC4R activation can modulate GnRH neurons directly, raising theoretical concerns about whether exogenous MC4R agonism during puberty could affect reproductive axis maturation. [7] No human trial has tested this question for bremelanotide specifically.

The Phase 3 Evidence Base: Who Was Actually Studied?

The key trials that led to FDA approval enrolled only adults. Understanding their design clarifies what is and is not known.

RECONNECT Trials (Studies BB-301 and BB-302)

The two Phase 3 RECONNECT trials enrolled a combined 1,247 premenopausal women with HSDD. Mean participant age was 38.2 years in BB-301 and 37.9 years in BB-302. The youngest enrolled participant was 22 years old. [8] Bremelanotide 1.75 mg produced statistically significant improvements in the Female Sexual Function Index desire domain score and reductions in distress scores on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) questionnaire compared with placebo (P<0.001 for both co-primary endpoints). [8]

Because no participant in RECONNECT was under 22, extrapolating efficacy data to a 16- or 17-year-old requires an assumption that the mechanism of action, receptor density, and neuroplasticity profile are equivalent. That assumption is not supported by published pharmacokinetic or pharmacodynamic data in adolescents. [3]

Nausea and Cardiovascular Signal

Nausea occurred in 40.4% of bremelanotide-treated participants versus 1.3% of placebo participants across the RECONNECT program. [8] Flushing occurred in 20.3% and headache in 11.0%. The blood pressure signal is particularly relevant for adolescents: bremelanotide transiently raised mean systolic blood pressure by approximately 2-4 mmHg, with the peak effect at roughly 4 hours post-dose and resolution by 12 hours. [1] In adolescents with undiagnosed primary hypertension, which affects an estimated 3.5% of U.S. Teens, this transient rise could carry more consequence than in a fully screened adult cohort. [9]

Transition Planning: A Structured Approach

Transitioning any adolescent patient from pediatric to adult care requires deliberate planning. When bremelanotide is part of that picture, whether as a drug the patient will become eligible for at 18 or one being managed off-label until that birthday, the transition plan needs extra specificity.

The 12-Month Handoff Window

The Society for Adolescent Health and Medicine recommends initiating care-transition planning at least 12 months before a defined age threshold. [10] Applied to bremelanotide eligibility, this means a prescriber should begin the conversation with a 16-to-17-year-old patient about what changes at 18: the drug becomes on-label, insurance coverage opens up, and the adult-care provider assumes primary responsibility. Key elements of the handoff include:

1. A written medical summary transferred to the adult provider that documents prior diagnoses, SSRI history if relevant, cardiovascular screening results, and any prior off-label bremelanotide exposures.
2. A baseline blood pressure measurement with documentation that resting BP is below 130/80 mmHg, as required before initiating bremelanotide per FDA prescribing information. [1]
3. Confirmation that the patient understands the injection technique and the 45-minute pre-activity administration window.
4. A self-care skills assessment. Research by Schwartz et al. In adolescents with chronic conditions shows that patients who can verbalize their diagnosis, name their medications, and contact their own provider have significantly better continuity outcomes post-transition. [11]

Cardiovascular Screening Before the First Adult Prescription

The FDA label for bremelanotide includes a contraindication for patients with known cardiovascular disease and a warning about transient blood pressure elevation. [1] For an 18-year-old receiving their first on-label prescription, the adult provider should confirm the absence of:

• Uncontrolled hypertension (BP at or above 130/80 mmHg at rest).
• Structural cardiac disease, including unrepaired congenital heart defects, which may persist from childhood.
• Use of nitrates, which cause an additive hypotensive interaction with bremelanotide.

The American Heart Association's 2017 hypertension guideline reclassified stage 1 hypertension to a systolic threshold of 130 mmHg. [12] Applying that standard to the pre-bremelanotide screen means a meaningful proportion of 18-year-olds with elevated-normal BP from adolescence may need BP optimization before starting the drug.

Addressing Comorbid Depression and SSRI Use

HSDD in adolescents and young adults is frequently iatrogenic, driven by SSRIs prescribed for depression or anxiety. Sertraline, escitalopram, and fluoxetine are all associated with decreased libido scores in adult trials, and observational data suggest similar effects in adolescents. [4] Before attributing reduced desire to a primary disorder warranting bremelanotide, the adult provider receiving this patient at 18 should:

• Evaluate whether SSRI-induced sexual dysfunction was the reason for initial evaluation.
• Consider dose reduction, switching to bupropion (which has a lower sexual side-effect profile), or adding augmentation strategies. [13]
• Reserve bremelanotide for cases where desire distress persists after SSRI management is optimized.

Safety Monitoring During and After Transition

Blood Pressure Protocol

Every bremelanotide injection requires a pre-dose blood pressure check. The FDA label specifies that the drug should not be used in patients with resting BP at or above 130/80 mmHg. [1] Pediatric providers handing off to adult teams must communicate any history of elevated BP readings, particularly given that adolescent hypertension often goes undiagnosed. The CDC reports that among U.S. Adolescents aged 12-19, approximately 3.5% meet criteria for hypertension and another 10.5% have elevated blood pressure. [9]

Hyperpigmentation Monitoring

Focal hyperpigmentation of the face, breasts, and gums was reported in approximately 1% of bremelanotide-treated patients in Phase 3 trials after chronic use. [8] This effect is mediated through MC1R activation and is more likely to occur in patients with darker baseline skin tones and with repeated dosing. Adolescent patients transitioning to adult care should be counseled that this risk persists with continued use and may not fully reverse after discontinuation. Dermatology referral is appropriate if new facial hyperpigmentation appears within 3 months of starting regular use. [1]

Drug Interactions Relevant to Adolescents

Bremelanotide slows gastric emptying, which can reduce the rate and extent of absorption of orally co-administered drugs. [1] In adolescent and young adult patients taking oral contraceptives, this interaction is clinically significant. The FDA prescribing information advises patients to take orally administered drugs at least 1 hour before bremelanotide injection to avoid reduced absorption. [1] This counseling point is frequently missed at transition, when the adult provider may not be aware of the patient's full contraceptive history established in pediatric care.

Interactions with naltrexone also require attention. Naltrexone is prescribed for opioid use disorder in adolescents with increasing frequency following changes to buprenorphine prescribing rules. Bremelanotide binds to opioid receptors as a partial agonist, and concurrent use with naltrexone may reduce bremelanotide's efficacy. [1, 14]

Psychological and Ethical Dimensions of Transitioning Adolescents

Assent, Consent, and Capacity

Adolescents aged 12-17 can provide assent (not full legal consent) for medical decisions in most U.S. States. When bremelanotide is discussed in the pre-transition period, the provider should document that the adolescent understands: the drug is not FDA-approved for their age group, it carries cardiovascular risk, and nausea occurs in roughly 4 in 10 users. Research on adolescent health literacy shows that comprehension of medication risk information is substantially lower in patients under 16 compared with those 18 and older. [15] Written materials should use a 6th-grade reading level as a baseline, per plain-language standards from the National Institutes of Health. [16]

Psychosexual Development Context

Sexual desire in adolescence is shaped by hormonal development, relationship context, trauma history, and gender identity factors. A meta-analysis by Simons and Carey (2001, N=52 studies) found HSDD prevalence estimates ranging from 0% to 3% across studies using structured diagnostic criteria, with significant methodological variation. [17] More recent estimates using DSM-5 criteria for Female Sexual Interest/Arousal Disorder (FSIAD) place 12-month prevalence at approximately 8.9% in adult women. [18] No validated prevalence data exist for FSIAD in patients aged 12-17, and applying adult diagnostic constructs to adolescents without developmental adaptation risks pathologizing normal variation in desire during puberty. [19]

The American College of Obstetricians and Gynecologists explicitly recommends that providers assess psychosocial, relational, and developmental context before attributing sexual complaints to a biologically treatable condition in adolescent patients. [5]

Practical Prescribing at the Transition Visit

What the Adult Provider Should Do on Day One

When a newly 18-year-old patient arrives at an adult practice asking about bremelanotide, a structured first visit should cover:

• Blood pressure measurement. If BP is 130/80 mmHg or above, defer the prescription and initiate antihypertensive evaluation.
• Medication reconciliation with specific attention to oral contraceptives, SSRIs, naltrexone, and nitrates.
• A validated desire/distress measure. The FSDS-DAO was used in the RECONNECT trials and takes under 5 minutes to administer. A score above 11 on the distress subscale supports a HSDD diagnosis in adults. [8, 20]
• Injection training or confirmation that the patient can self-administer the autoinjector correctly into the abdomen, thigh, or upper arm.
• Documentation that nausea management has been discussed; the FDA label notes that nausea is the primary reason for discontinuation in clinical trials. [1]

Dosing Specifics

Bremelanotide is supplied as a 1.75 mg/0.4 mL prefilled autoinjector. The approved dose is 1.75 mg subcutaneously, administered no sooner than 45 minutes before anticipated sexual activity. No more than one dose in 24 hours is permitted. The FDA label also states that the drug should not be used more than once every 24 hours, and that outcomes data beyond 52 weeks of use are limited. [1] Patients should be advised not to exceed 8 doses per month based on trial exposure patterns, though the label does not set a fixed monthly cap. [8]

Frequently Asked Questions